Veru (NASDAQ:VERU – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01, Zacks reports. Veru had a negative net margin of 223.85% and a negative return on equity of 92.88%.
Veru Trading Down 7.6 %
Shares of VERU traded down $0.04 during mid-day trading on Thursday, hitting $0.51. 2,887,448 shares of the company’s stock were exchanged, compared to its average volume of 5,203,067. The firm has a market capitalization of $74.36 million, a P/E ratio of -1.81 and a beta of -0.54. Veru has a fifty-two week low of $0.37 and a fifty-two week high of $1.92. The business’s 50 day moving average is $0.72 and its two-hundred day moving average is $0.77.
Analyst Upgrades and Downgrades
VERU has been the subject of several analyst reports. Oppenheimer reiterated an “outperform” rating and issued a $5.00 price objective on shares of Veru in a research report on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of Veru in a research report on Thursday, January 2nd.
About Veru
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Featured Stories
- Five stocks we like better than Veru
- The Significance of Brokerage Rankings in Stock Selection
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- Short Selling – The Pros and Cons
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- CVS Health: Earnings Beat Ignites Stock Rally
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.